Amesika Nyaku, ACTHIV 2022: New antiretroviral agents in the treatment of HIV

There are number of new and emerging antiretroviral agents for the treatment of HIV. Dr Amesika Nyaku (Rutgers New Jersey Medical School, Newark, NJ, USA) discusses different antiretroviral therapies, including long-acting cabotegravir and long-acting rilivirine, the use of fostemsavir and in whom this treatment benefits most, and management of missed doses.

View more content from Dr Amesika Nyaku: Future directions in HIV research

The presentation entitled: ‘New Antiretroviral Agents and When to Use Them’ was presented at the American Conference for the Treatment of HIV (ACTHIV), May 5-7, 2022.

Questions:

1. What is the mechanism of action of the long-acting cabotegravir and long-acting rilpivirine? (0:16)
2. What are the cautions/contraindications of these drugs? (1:33)
3. How should missed doses be managed? (3:28)
4. Could you tell us a little about fostemsavir and the patients most likely to benefit from it? (6:31)

Disclosures: Amesika Nyaku has nothing to disclose in relation to this video interview.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.

Filmed as a highlight of ACTHIV 2022